Literature DB >> 7580184

Treatment of depression in Parkinson's disease: a meta-analysis.

T Klaassen1, F R Verhey, G H Sneijders, N Rozendaal, H C de Vet, H M van Praag.   

Abstract

Despite a 40% prevalence of depression in idiopathic Parkinson's disease (PD), an extensive literature search found only 12 controlled studies of treatment efficacy. A meta-analysis of these was performed in pursuit of guidelines for pharmacological treatment. Articles were scored on a scale from 0 to 100 on a specially adapted list of methodological criteria. Only 4 articles scored more than 50 points, and these generally did not use depression rating scales. Thus, there are virtually no empirical data on the treatment of depression in PD. Further studies are urgently needed, both for the sake of patient care and to gain a better understanding of the pathophysiological mechanisms underlying depression in PD and the interrelation between depression and cognitive decline.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7580184     DOI: 10.1176/jnp.7.3.281

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  15 in total

Review 1.  Neuropsychiatric aspects of Parkinson's disease.

Authors:  D Aarsland; K Karlsen
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

2.  Nonrecognition of depression in Parkinson's disease.

Authors:  Karen E Anderson
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

3.  Depression in Parkinson's Disease.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

4.  Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa.

Authors:  D A M C van de Vijver; R A C Roos; P A F Jansen; A J Porsius; A de Boer
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

Review 5.  Depression in Parkinson's disease. Pharmacological characteristics and treatment.

Authors:  T Tom; J L Cummings
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

Review 6.  Neuropsychiatric aspects of Parkinson's disease: recent advances.

Authors:  Laura Marsh; Ariel Berk
Journal:  Curr Psychiatry Rep       Date:  2003-05       Impact factor: 5.285

Review 7.  Antidepressant studies in Parkinson's disease: a review and meta-analysis.

Authors:  Daniel Weintraub; Knashawn H Morales; Paul J Moberg; Warren B Bilker; Catherine Balderston; John E Duda; Ira R Katz; Matthew B Stern
Journal:  Mov Disord       Date:  2005-09       Impact factor: 10.338

Review 8.  Psychiatric symptoms in Parkinson's disease.

Authors:  Karen E Anderson; William J Weiner
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

Review 9.  Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Petros Skapinakis; Eleni Bakola; Georgia Salanti; Glyn Lewis; Athanasios P Kyritsis; Venetsanos Mavreas
Journal:  BMC Neurol       Date:  2010-06-21       Impact factor: 2.474

10.  Coaxil (tianeptine) in the treatment of depression in Parkinson's disease.

Authors:  O S Levin
Journal:  Neurosci Behav Physiol       Date:  2007-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.